Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

  • Showing results for a modified search because your search retrieved no results.
1.

Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma.

Li X, Chen ZH, Ma XK, Chen J, Wu DH, Lin Q, Dong M, Wei L, Wang TT, Ruan DY, Lin ZX, Xing YF, Deng Y, Wu XY, Wen JY.

Tumour Biol. 2014 Nov;35(11):11057-63. doi: 10.1007/s13277-014-2360-8. Epub 2014 Aug 6. Erratum in: Tumour Biol. 2016 Sep;37(9):12903.

PMID:
25095975
2.

Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection.

Huang GQ, Zhu GQ, Liu YL, Wang LR, Braddock M, Zheng MH, Zhou MT.

Oncotarget. 2016 Feb 2;7(5):5429-39. doi: 10.18632/oncotarget.6707.

3.

Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma.

Li X, Chen ZH, Xing YF, Wang TT, Wu DH, Wen JY, Chen J, Lin Q, Dong M, Wei L, Ruan DY, Lin ZX, Wu XY, Ma XK.

Tumour Biol. 2015 Apr;36(4):2263-9. doi: 10.1007/s13277-014-2833-9. Epub 2014 Nov 21.

PMID:
25409616
4.

The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib.

Zheng YB, Zhao W, Liu B, Lu LG, He X, Huang JW, Li Y, Hu BS.

Asian Pac J Cancer Prev. 2013;14(9):5527-31.

5.
6.

Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma.

Gao F, Li X, Geng M, Ye X, Liu H, Liu Y, Wan G, Wang X.

Medicine (Baltimore). 2015 Mar;94(11):e639. doi: 10.1097/MD.0000000000000639.

7.

Preoperative Neutrophil to Lymphocyte Ratio as a Prognostic Factor in Patients with Non-metastatic Renal Cell Carcinoma.

Wen RM, Zhang YJ, Ma S, Xu YL, Chen YS, Li HL, Bai J, Zheng JN.

Asian Pac J Cancer Prev. 2015;16(9):3703-8.

8.

[Preoperative neutrophil-lymphocyte ratio as a prognostic predictor after liver transplantation for hepatocellular carcinoma].

Wang GY, Yang Y, Zhang Q, Li H, Chen GZ, Yi SH, Xu C, Wang GS, Zhang J, Yi HM, Jiang N, Fu BS, Zhao H, Li MR, Chen YH, Cai CJ, Lu MQ, Chen GH.

Zhonghua Yi Xue Za Zhi. 2011 Jun 14;91(22):1519-22. Chinese.

PMID:
21914362
9.

Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.

McNally ME, Martinez A, Khabiri H, Guy G, Michaels AJ, Hanje J, Kirkpatrick R, Bloomston M, Schmidt CR.

Ann Surg Oncol. 2013 Mar;20(3):923-8. doi: 10.1245/s10434-012-2639-1. Epub 2012 Sep 11.

PMID:
22965570
10.

Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer.

Lian L, Xia YY, Zhou C, Shen XM, Li XL, Han SG, Zheng Y, Mao ZQ, Gong FR, Wu MY, Chen K, Tao M, Li W.

Cancer Biomark. 2015;15(6):899-907. doi: 10.3233/CBM-150534.

PMID:
26444485
11.

Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer.

Ock CY, Nam AR, Lee J, Bang JH, Lee KH, Han SW, Kim TY, Im SA, Kim TY, Bang YJ, Oh DY.

Gastric Cancer. 2017 Mar;20(2):254-262. doi: 10.1007/s10120-016-0613-5. Epub 2016 May 5.

PMID:
27147244
12.

Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy.

Fu SJ, Shen SL, Li SQ, Hua YP, Hu WJ, Liang LJ, Peng BG.

Med Oncol. 2013 Dec;30(4):721. doi: 10.1007/s12032-013-0721-6. Epub 2013 Sep 13.

PMID:
24026659
13.

Postoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes of hepatocellular carcinoma.

Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ.

J Surg Res. 2015 Sep;198(1):73-9. doi: 10.1016/j.jss.2015.05.003. Epub 2015 May 7.

PMID:
26022997
14.

Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.

da Fonseca LG, Barroso-Sousa R, Bento Ada S, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J.

Med Oncol. 2014 Nov;31(11):264. doi: 10.1007/s12032-014-0264-5. Epub 2014 Oct 2.

PMID:
25273866
15.

The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization.

Sukato DC, Tohme S, Chalhoub D, Han K, Zajko A, Amesur N, Orons P, Marsh JW, Geller DA, Tsung A.

J Vasc Interv Radiol. 2015 Jun;26(6):816-24.e1. doi: 10.1016/j.jvir.2015.01.038. Epub 2015 Mar 29.

PMID:
25824315
16.

Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.

Zhang W, Zhao G, Wei K, Zhang Q, Ma W, Wu Q, Zhang T, Kong D, Li Q, Song T.

Med Oncol. 2015 Apr;32(4):107. doi: 10.1007/s12032-015-0549-3. Epub 2015 Mar 7.

PMID:
25750040
17.

Neutrophil-to-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma: a Western perspective.

Sullivan KM, Groeschl RT, Turaga KK, Tsai S, Christians KK, White SB, Rilling WS, Pilgrim CH, Gamblin TC.

J Surg Oncol. 2014 Feb;109(2):95-7. doi: 10.1002/jso.23448. Epub 2013 Oct 4.

PMID:
24122764
18.

Preoperative neutrophil-to-lymphocyte ratio is a more valuable prognostic factor than platelet-to-lymphocyte ratio for nonmetastatic rectal cancer.

Li H, Song J, Cao M, Wang G, Li L, Zhang B, Li Y, Xu W, Zheng J.

Int Immunopharmacol. 2016 Nov;40:327-331. doi: 10.1016/j.intimp.2016.09.014. Epub 2016 Sep 21.

PMID:
27664571
19.

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization.

Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J.

PLoS One. 2015 Mar 5;10(3):e0119312. doi: 10.1371/journal.pone.0119312. eCollection 2015.

20.

The Severity of Liver Fibrosis Influences the Prognostic Value of Inflammation-Based Scores in Hepatitis B-Associated Hepatocellular Carcinoma.

Wang Q, Blank S, Fiel MI, Kadri H, Luan W, Warren L, Zhu A, Deaderick PA, Sarpel U, Labow DM, Hiotis SP.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1125-32. doi: 10.1245/s10434-015-4598-9. Epub 2015 Jul 10.

PMID:
26159441

Supplemental Content

Support Center